<DOC>
	<DOCNO>NCT01050907</DOCNO>
	<brief_summary>The purpose Treatment IND make miltefosine available mucocutaneous leishmaniasis patient present United States . If entrance criterion meet , subject mucosal cutaneous leishmaniasis receive miltefosine target dose 2.5 mg/kg/day 28 day . During treatment week 1 , 2 , 4 , patient return treatment facility assess adverse event . Blood transaminase creatinine value draw midpoint end therapy . Patients return treatment facility examine clinically 6 wks ( ie , 2 wks end therapy ) , 3 month ( 2 month therapy ) , 7 month ( 6 month treatment ) ML CL patient , also 13 month ( 12 month treatment ) ML patient .</brief_summary>
	<brief_title>Miltefosine Treat Mucocutaneous Leishmaniasis</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Leishmaniasis , Mucocutaneous</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>1 . Is subject male female least 18 year age ? 2 . Does subject weigh least 30 kg ? 3 . Does subject diagnosis ML CL least one lesion least one follow method : 1 ) positive culture promastigotes lesion material , 2 ) microscopic identification amastigotes stain lesion tissue , 3 ) PCR lesion material ? 4 . In opinion investigator , subject capable understanding comply protocol ? 5 . If female childbearing potential , subject negative pregnancy test screen agree use acceptable method birth control treatment phase 6 month treatment complete ? 6 . Has patient sign informed consent ? 1 . Is subject female breastfeeding ? 2 . Does subject clinically significant medical disorder ? Thrombocyte count &lt; 100 x 109/l Leukocyte count &lt; 3 x 109/l Haemoglobin &lt; 10 g/100 ml ASAT , ALAT &gt; 2 time upper limit normal range Bilirubin &gt; 1.5 time upper limit normal range Serum creatinine &gt; 1.5 time upper limit normal range Major surgery within last 2 week Any noncompensated uncontrolled condition 3 . In last 4 week present , subject receive treatment leishmaniasis , include medication pentavalent antimony ; amphotericin B , paromomycin , imidazole ?</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>leishmaniasis</keyword>
	<keyword>cutaneous disease</keyword>
	<keyword>mucosal disease</keyword>
	<keyword>miltefosine</keyword>
</DOC>